Eidos therapeutics, inc. (EIDX)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Assets
Current assets:
Cash and cash equivalents

196,500

191,200

165,822

131,400

147,064

157,147

166,568

176,689

25,269

5,497

Related party receivable

125

85

83

197

72

34

29

21

76

67

Prepaid expenses and other current assets

3,952

4,678

5,402

3,928

2,160

1,789

3,248

2,245

624

484

Total current assets

200,592

195,920

171,307

135,525

149,296

158,970

169,845

178,955

25,969

6,048

Property and equipment, net

1,283

1,259

1,199

204

196

209

218

219

218

114

Operating lease, right of use asset

3,900

4,010

4,121

988

1,053

-

-

-

-

-

Other assets

2,825

2,631

2,267

2,564

2,652

933

163

169

1,109

181

Total assets

208,597

203,820

178,894

139,281

153,197

160,112

170,226

179,343

27,296

6,343

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

3,972

3,151

3,567

1,842

3,212

1,956

2,417

2,134

1,667

566

Related party payable

323

316

372

344

407

256

206

531

327

372

Lease liabilities

569

554

471

276

269

-

-

-

-

-

Accrued expenses and other current liabilities

6,956

6,409

5,665

4,027

3,953

2,577

3,427

2,631

2,744

1,300

Total current liabilities

11,820

10,430

10,075

6,489

7,841

4,789

6,050

5,296

4,738

2,238

Debt, non-current

16,316

16,112

-

-

-

-

-

-

-

-

Lease liabilities, non-current

4,443

4,591

4,736

782

854

-

-

-

-

-

Embedded derivative

1,103

1,165

-

-

-

-

-

-

-

-

Other liabilities

63

95

129

164

201

316

357

403

439

273

Total liabilities

33,745

32,393

14,940

7,435

8,896

5,105

6,407

5,699

6,082

2,511

Redeemable convertible preferred stock, $0.001 par value; 0 and 14,000,000 shares authorized as of December 31, 2018 and December 31, 2017, respectively; 0 and 12,856,325 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively; aggregate liquidation preference of $17,032 as of December 31, 2017;

-

-

-

-

-

-

-

-

47,195

17,028

Stockholders’ equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2020 and December 31, 2019, respectively; 38,528,841 and 38,040,693 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

39

38

38

37

37

37

37

37

4

4

Additional paid-in-capital

300,742

274,494

248,041

222,865

221,267

220,240

219,196

218,409

7,436

1,332

Accumulated deficit

-125,900

-103,105

-84,125

-91,056

-77,003

-65,270

-55,414

-44,802

-33,421

-14,532

Total stockholders’ equity

174,852

171,427

163,954

131,846

144,301

155,007

163,819

173,644

-25,981

-13,196

Total liabilities and stockholders' equity

208,597

203,820

178,894

139,281

153,197

160,112

170,226

179,343

27,296

6,343